USDA Accepts Supplemental Biologics License Application for Yervoy As Adjuvant Treatment for Patients with Stage 3 Melanoma Who Are at High Risk of Recurrence

By: via Benzinga
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.